Drug Patents owned by Johnson Johnson Visn
1. List of Acuvue Theravision With Ketotifen drug patents
ACUVUE THERAVISION WITH KETOTIFEN Litigations
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9474746 | JOHNSON JOHNSON VISN | Methods for stabilizing oxidatively unstable compositions |
Mar, 2028
(4 years from now) | |
| US9962376 | JOHNSON JOHNSON VISN | Methods and ophthalmic devices used in the treatment of ocular allergies |
Jun, 2030
(7 years from now) | |
Do you want to check out ACUVUE THERAVISION WITH KETOTIFEN patents from before 2022?
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Feb 25, 2025 |
Drugs and Companies using KETOTIFEN FUMARATE ingredient
Market Authorisation Date: 25 February, 2022
Treatment: NA
Dosage: DRUG-ELUTING CONTACT LENS ;OPHTHALMIC
More Information on Dosage
ACUVUE THERAVISION WITH KETOTIFEN family patents
11
United States
6
European Union
4
Korea, Republic of
3
Russia
3
Hong Kong
3
China
3
Canada
2
Spain
2
Brazil
2
Taiwan
2
Argentina
2
Japan
2
Australia
1
Singapore
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic